
The complete response letter (CRL) did not raise safety concerns, but stated the IGNYTE trial was inadequate and did not provide substantial evidence of effectiveness.

The complete response letter (CRL) did not raise safety concerns, but stated the IGNYTE trial was inadequate and did not provide substantial evidence of effectiveness.

In the double-blind portion of Vibrance-1, alixorexton improved wakefulness while eliciting broad benefits in patient-reported outcomes.

With AI-enhanced pharmacogenetics, pharmacists lead the shift to truly individualized medicine.

Administering influenza, COVID-19, and RSV immunizations at the same time may improve vaccine uptake.

From AI-powered prescription fulfillment to the expansion of PillPack for Medicare patients, Carey outlines how Amazon Pharmacy is streamlining access, improving affordability, and setting the stage for a more patient-centered health care future.

Pharmacy deserts can have far-reaching consequences, especially in rural and low-income communities.

Andrew H. Wei, PhD, discusses phase 1b findings on the safety, pharmacokinetics, and preliminary efficacy of combining the menin inhibitor bleximenib with venetoclax and azacitidine in patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) harboring NPM1 mutations or KMT2A rearrangements.

Challenges faced by individuals living with HIV include weight gain, cardiovascular risks, and healthy aging strategies.

A pharmacist's termination raises critical questions about staffing policies, patient safety, and ethical obligations in healthcare. Explore the ongoing legal battle.

Critically ill patients treated with a pharmacist-managed insulin protocol achieved higher rates of glucose control than those treated with conventional methods.

Different dietary strategies, including intermittent energy restriction, enhance weight loss and blood sugar control in those with type 2 diabetes (T2D) and obesity.

GLP-1 anti-obesity medications enhance testosterone levels, aiding weight management and improving health outcomes for those with obesity and type 2 diabetes (T2D).

These tools provide real-time data, enabling earlier intervention and prevention of serious health complications.

Pharmacists play a critical role in preventing medication ordering errors during residency onboarding through proactive training, system safeguards, and interdisciplinary collaboration.

Neladalkib enters phase 3 trials, targeting advanced ALK-positive NSCLC, promising improved outcomes for TKI-naive patients with brain metastases.

Lessons from the past season could strengthen prevention and drive vaccinations for 2025-2026.

Omolola (Lola) Adeoye-Olatunde, PharmD, MS, discusses findings from a multi-year analysis of American Association of Colleges of Pharmacy (AACP) institutional data on faculty and graduate student representation in pharmacy education, highlighting persistent disparities and offering actionable strategies to improve equity and inclusion in the academic pipeline.

Nikita Dahake, MD; Hossein Borghaei, DO, MS; and Yasmine Baca, MS, PhD candidate, MB(ASCP)CM, explore how distinct HER2-alteration subtypes in non-small cell lung cancer (NSCLC) impact survival outcomes, co-mutation profiles, and treatment response to immunotherapy-based regimens.

Franck Morschhauser, MD, PhD, discusses the novel cereblon-dependent bifunctional degrader BMS-986458, highlighting its selective targeting of BCL6, promising early efficacy in relapsed/refractory lymphoma, favorable safety profile, and future potential in combination regimens and earlier treatment lines.

Influenza vaccination significantly reduces cases and enhances community immunity, highlighting pharmacists' vital role in promoting public health.

Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action.

Education initiatives, facilitation, and immunization on the part of pharmacists were found to significantly increase uptake of pneumococcal vaccines among older adults.

The advisory committee cited concerns around ocular toxicity and overall tolerability, raising serious questions about the drug's benefit-risk profile ahead of its scheduled Prescription Drug User Fee Act action date on July 23, 2025.

The CRL states that the STARGLO data do not provide sufficient evidence to support the second-line indication in the US patient population.

Long-term obesity accelerates aging in young adults, increasing risks for cardiovascular diseases and metabolic dysfunction.

ImCheck's ICT01 gains an orphan drug designation from the FDA, offering hope for acute myeloid leukemia (AML) treatment in older patients with limited options.

Researchers unveil a groundbreaking method using polypurine hairpins to inhibit PCSK9, offering a promising alternative for lowering cholesterol and reducing cardiovascular risk.

Immunocompromised patients, especially transplant recipients, face heightened RSV risks, leading to severe infections and complications.

The updated version 1.2026 NCCN Guidelines for chronic myeloid leukemia (CML) emphasize individualized treatment strategies, TKI-specific considerations, drug interaction management, and pregnancy safety, highlighting the critical role of oncology pharmacists in optimizing therapy selection, patient counseling, and cost-effective care.

The National Comprehensive Cancer Network (NCCN) has released multiple myeloma guidelines version 2.2026 to include linvoseltamab as a preferred treatment for heavily pretreated patients, highlighting its intravenous formulation, dosing options, and streamlined Risk Evaluation and Mitigation Strategy program.